期刊文献+

阿哌沙班和利伐沙班在全膝关节表面置换术后抗凝效果的对比 被引量:1

原文传递
导出
摘要 目的观察对比阿哌沙班和利伐沙班在全膝关节表面置换术后的抗凝效果。方法选取该院自2013年4月—2016年4月进行全膝关节表面置换手术的患者50例,随机均分为观察组和对照组(n=25),所有患者进行骨科常规手术,术后彻底止血确认无明显出血和渗血情况。观察组患者25例,使用阿哌沙班进行治疗,术后8 h开始口服阿哌沙班2.5 mg,连续服用14 d;对照组患者25例,使用利法沙班进行治疗,术后8 h开始口服利法沙班10 mg,连续服用14 d,观察对比两组患者术后抗凝效果,观察有无静脉血栓形成,术后失血,皮下瘀斑的发生情况。结果观察组和比较组患者,在术后均无明显的出血现象,无静脉血栓形成,对比结果差异无统计学意义(P>0.05)。观察组25例患者,在使用阿哌沙班进行治疗后,出现皮下瘀斑的患者为7例,皮下瘀斑发生率28%;比较组25例患者,在使用利伐沙班进行治疗后,出现皮下瘀斑患者为15例,皮下瘀斑发生率为60%(P<0.05),观察组患者皮下瘀斑发生率远低于对照组。结论全膝关节表面置换术后患者口服阿哌沙班和利伐沙班均无明显的出血现象发生,无静脉血栓形成显性效果无明显差异,但口服阿哌沙班的观察组患者的皮下瘀斑发生率,明显低于口服利法沙班的对比组患者,所以阿哌沙班在全膝关节表面置换术后抗凝效果更加有效,值得临床推广。
作者 张传广
出处 《双足与保健》 2017年第9期127-127,129,共2页 Biped and Health
  • 相关文献

参考文献2

二级参考文献44

  • 1Januel JM, Chen G, Rrffieux C, et al. Symptomatic in- hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiv- ing recommended prophylaxis : a systematic review [ J ]. Jama, 2012, 307 (3) : 294-303.
  • 2CarR AJ, Robertsson O, Graves S, et al. Knee replace- ment [J]. Lancet, 2012, 379 (9823) : 1331-1340.
  • 3Corti MC, Rigon C. Epidemiology of osteoarthritis : prev- alence, risk factors and functional impact [ J ]. Aging Clin Exp Res, 2003, 15 (5) : 359-363.
  • 4Van Manen, Nace J, Mont MA. Management of Primary Knee Osteoarthritis and Indications for Total Knee Arthro- plasty for General Practitioners [ J ]. J Am Osteopath Assoc, 2012 (11): 709-715.
  • 5Dixon T, Shaw M, Ebrahim S, et al. Trends in hip and knee joint replacement: socioeconomic inequalities and projections of need [ J]. Ann Rheum Dis, 2004, 63 (7) : 825-830.
  • 6Falck-ytter Y, Francis CW, Johanson NA, et al. Preven- tion of VTE in orthopedic surgery patients : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Prac- tice Guidelines [ J]. Chest, 2012, 141 (2 Suppl) : e278S-325S.
  • 7Jameson SS, Rymaszewska M, HUI AC, et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight hepa-fins for thromboprophylaxis in lower limb arthroplasty [J]. J Bone Joint Surg Am, 2012, 94 (17): 1554- 1558.
  • 8Russell RD, Huo MH. Apixaban and rivaroxaban de- crease deep venous thrombosis but not other complica- tions after total hip and total knee arthroplasty [ J ]. J Arthroplasty, 2013, 28 (9): 1477-1481.
  • 9Beyer-westendorf J, Lutzner J, Donath L, et al. Efficacy and safety of rivaroxaban or fondaparinux thromboprophy- 1axis in major orthopedic surgery: findings from the OR-THO-TEP registry [J]. J Thromb Haemost, 2012, 10 (10) : 2045-2052.
  • 10Gomez-outes SA, Terleira-fernandez AI, SUAREZ-GEA M L, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement : systematic review, meta-analysis, and indi- rect treatment comparisons [ J]. BMJ, 2012 (344) : e3675.

共引文献12

同被引文献15

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部